Biodesix (BDSX) Expected to Announce Earnings on Monday

Biodesix (NASDAQ:BDSX) is expected to be announcing its earnings results after the market closes on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $19.92 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Biodesix Price Performance

NASDAQ:BDSX opened at $0.88 on Monday. Biodesix has a 12 month low of $0.86 and a 12 month high of $2.04. The stock has a 50 day moving average of $1.19 and a two-hundred day moving average of $1.46. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The firm has a market cap of $128.30 million, a P/E ratio of -2.26 and a beta of 1.06.

Insiders Place Their Bets

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 128,702 shares of company stock worth $118,406. Corporate insiders own 69.20% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.